Surmodics (SRDX) Receives Daily Media Sentiment Score of 0.22

News headlines about Surmodics (NASDAQ:SRDX) have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Surmodics earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.8654585232637 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

SRDX has been the topic of several research reports. BidaskClub cut Surmodics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. ValuEngine cut Surmodics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Aegis initiated coverage on Surmodics in a research note on Tuesday, June 27th. They issued a “buy” rating on the stock. Finally, Lake Street Capital initiated coverage on Surmodics in a research note on Friday, July 14th. They issued a “buy” rating and a $40.00 target price on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $34.33.

Surmodics (NASDAQ SRDX) traded down 1.10% on Tuesday, hitting $27.05. The company’s stock had a trading volume of 20,423 shares. The firm has a 50 day moving average of $26.02 and a 200-day moving average of $24.99. The stock has a market cap of $354.60 million, a PE ratio of 58.93 and a beta of 0.85. Surmodics has a 12 month low of $21.90 and a 12 month high of $30.75.

Surmodics (NASDAQ:SRDX) last announced its earnings results on Thursday, August 3rd. The company reported $0.09 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.10. Surmodics had a return on equity of 7.28% and a net margin of 8.66%. The company had revenue of $17.80 million for the quarter, compared to analysts’ expectations of $15.98 million. During the same period last year, the firm earned $0.37 EPS. Surmodics’s revenue for the quarter was down 11.0% compared to the same quarter last year. On average, analysts expect that Surmodics will post $0.31 earnings per share for the current fiscal year.

In related news, CEO Gary R. Maharaj sold 5,000 shares of the firm’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $28.03, for a total value of $140,150.00. Following the transaction, the chief executive officer now directly owns 131,807 shares of the company’s stock, valued at approximately $3,694,550.21. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Bryan K. Phillips sold 1,226 shares of the firm’s stock in a transaction on Friday, June 16th. The stock was sold at an average price of $24.85, for a total value of $30,466.10. Following the completion of the transaction, the senior vice president now directly owns 29,208 shares in the company, valued at $725,818.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,226 shares of company stock worth $299,366. 6.40% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Surmodics (SRDX) Receives Daily Media Sentiment Score of 0.22” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at

Surmodics Company Profile

Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.

Insider Buying and Selling by Quarter for Surmodics (NASDAQ:SRDX)

Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply